GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic  alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.

Dodge & Cox Stock I

Vanguard PRIMECAP Inv

Vanguard PRIMECAP Core Inv

Fidelity Growth & Income

Fidelity Equity Dividend Income

Capital Group American Mutual Comp

American Funds American Mutual A

Mondrian Int Eq Delivered Strategy

Vanguard Windsor™ II Inv

First Trust Value Line® Dividend ETF

Dodge & Cox Worldwide US Stock A EUR

Douglas C. Lane & Assoc. Core Equity

Dodge & Cox Balanced Composite

Dodge & Cox Balanced I

T. Rowe Price International Val Eq Tr- A

Fidelity Series Large Cap Stock

T. Rowe Price International Value Equity

T. Rowe Price International Value Eq

Strategic Advisers Fidelity US TtlStk

Fidelity Select Pharmaceuticals Port

Dodge & Cox

FMR Inc

Mondrian Investment Partners Ltd

Eversept Partners, LLC

Provident Trust Company

Arrowstreet Capital Limited Partnership

Grantham, Mayo, Van Otterloo & Co., LLC

Hotchkis & Wiley Capital Management LLC

Equity Investment Corp

Camber Capital Management LLC

Dimensional Fund Advisors, Inc.

HSBC Holdings PLC

JTC Employer Solutions Trustee Ltd

Fisher Asset Management, LLC

PRIMECAP Management Company

Morgan Stanley - Brokerage Accounts

T. Rowe Price Associates, Inc.

Goldman Sachs Group Inc

Royal Bank of Canada

State Street Corp

GlaxoSmithKline PLC ADR

Ms. Emma Natasha Walmsley

CEO & Director

Ms. Julie Belita Brown A.C.A.

CFO & Executive Director

Ms. Shobie  Ramakrishnan

Chief Digital & Technology Officer

Mr. Tony  Wood

Chief Scientific Officer and Head of R&D

Ms. Sarah  Elton-Farr

Head of Investor Relations

Mr. James  Ford

Senior VP & Group General Counsel of Legal & Compliance

Ms. Sally  Jackson

Senior Vice President of Global Communications & CEO Office

Mr. David Simon Redfern BSc (Hons), CA

President of Corporate Development

Ms. Diana  Conrad

Chief People Officer

Mr. Philip C. Thomson

President of Global Affairs

GSK's next earnings is on February 5, 2025 (Before Market Open)

GSK's latest dividend is 0.38567 USD on August 16, 2024

GlaxoSmithKline PLC ADR (GSK) Stock Analysis, Discussion Forum and Financial Metrics - NYSE Exchange

GlaxoSmithKline PLC ADR (GSK) Earnings Report Date and History | NYSE

GSK's next earnings is on February 5, 2025 (Before Market Open)

When is the earnings report for GSK?

GSK Earnings History

GSK's latest dividend is 0.38567 USD on August 16, 2024

GSK Stock Discussion Forum and Message Board

News for NYSE: GSK